Trifas 20 (torasemide) solution for injections 20 mg/4 ml. vials №5

Description

Trifas 20 (torasemide) solution for injections 20 mg/4 ml. vials №5

Composition

active substance: torasemide;

1 ampoule (4 ml) of solution for injection contains 21.262 mg torasemide sodium (equivalent to 20 mg torasemide);

Excipients: sodium hydroxide, trometamol, polyethylene glycol 400, water for injections.

Dosage form

Solution for injection.

Basic physical and chemical properties: transparent, colorless solution that contains virtually no mechanical inclusions. pH of Trifas 20 ampoules 8.5-9.5.

Pharmacotherapeutic group

Diuretics. Highly active diuretics.
ATX code C0ZS A04.

Pharmacological properties

It is a loop diuretic. In low doses, it has a weak diuretic, saluretic (increase the release of sodium and potassium salts) effect. At a higher dose, increases diuresis (dose-dependent).

Indications

Trifas 20 solution are prescribed:
for the treatment of edema and / or effusion caused by insufficient heart function, if intravenous administration is necessary (for example, with pulmonary edema).

Contraindications

It is impossible to prescribe Trifas 20 solution:

• with intolerance to the components of the drug;
• with intolerance to sulfonylurea preparations;
• with renal failure with anuria;
• with hepatic precoma / coma;
• with arterial hypotension;
• with hypovolemia;
• with hyponatremia;
• with hypokalemia;
• in acute urinary disorders (for example, due to prostate hypertrophy);
• when breastfeeding;
• children.

Application during pregnancy and lactation

During pregnancy, Trifas 20 solution are used only for health reasons.
This medicine is not used during breastfeeding.

Method of administration and dosage

Trifas 20 solution are used parenterally (slowly intravenously).
For adults, treatment begins with a single dose of 2 ml (equivalent to 10 mg) per day. If the therapeutic effect is insufficient, the single dose is increased to 4 ml (20 mg). In case of insufficient effectiveness, short-term therapy (up to three days) can be applied using a dose of 8 ml (40 mg) per day.
In acute pulmonary edema, treatment begins with a single dose of 4 ml (20 mg). Depending on the achieved effect, the dose can be repeated at intervals of 30 minutes. It is forbidden to exceed the maximum daily dose – 20 ml (100 mg).
Patients with insufficient liver and / or kidney function require dose adjustment (possibly an increase in the concentration of the active substance in the blood).

Overdose

An overdose of Trifas 20 solution may be accompanied by increased diuresis, electrolyte imbalance, drowsiness, amentive syndrome (confusion, incoherence of speech, chaotic movements), symptomatic arterial hypotension, cardiovascular failure, digestive disorders.
Overdose treatment: dose reduction or drug withdrawal, fluid and electrolyte replacement (after appropriate control).

Side effects:

• Metabolic disorders: metabolic alkalosis, muscle spasms, hyperuricemia, hyperglycemia, hypercholesterolemia, hypertriglyceridemia, hypokalemia, disturbances in water and electrolyte balance (hypovolemia, hyponatremia, hypokalemia).
• Cardiovascular disorders: thrombosis, arterial hypotension, cerebral and cardiac ischemia, cardiac arrhythmias, syncope, angina pectoris, acute myocardial infarction.
• Digestive disorders: flatulence, loss of appetite, stomach pain, diarrhea, nausea / vomiting, constipation, pancreatitis.
• Urinary disorders: hypercreatininemia, urinary retention, urge to urinate.
• Hepatobiliary disorders: increased blood levels of γ-glutamyl transpeptidase.
• Hematological disorders: thrombocytopenia, erythrocytopenia, leukocytopenia.
• Dermatological disorders: allergic reactions (exanthema, pruritus, photosensitivity).